SECONDARY ERUPTIVE XANTHOMA AND NAEVUS UNIUS LATERIS WITH LIPOID NEPHROSIS
A. J. EDELSTEIN
core +1 more source
Obinutuzumab alone may be an effective option for adult minimal change disease: a single-center retrospective observational study. [PDF]
Bai Q, Tao LY, Zheng D, Wang Y.
europepmc +1 more source
COBALT-INDUCED HYPOTHYROIDISM AND POLYCYTHEMIA IN LIPOID NEPHROSIS
K. Kouvalainen +2 more
core +1 more source
Minimal Change Disease and FSGS Are a Spectrum of a Single Disease within Immune-Mediated Nephrotic Syndrome. [PDF]
Sim JJ, Smoyer WE, Schachter AD.
europepmc +1 more source
Cyclophosphamide in the treatment of idiopathic lipoid nephrosis
James N. Etteldorf +5 more
core +1 more source
A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING). [PDF]
C Willcocks L +11 more
europepmc +1 more source
LIPOID NEPHROSIS AND FOCAL GLOMERULOSCLEROSIS IN A PATIENT WITH POLYMYOSITIS
K.H. Fye, H. Moutsopoulos
core +1 more source
Minimal Change Nephrotic Syndrome Secondary to Methotrexate-associated Hodgkin Lymphoma. [PDF]
Iimori M +5 more
europepmc +1 more source
Rituximab for refractory minimal change disease: Long-term outcomes in the remission maintenance phase. [PDF]
Tian L +5 more
europepmc +1 more source

